Polymorphism

Men

Women

Control

n (%)

NSCLC

n (%)

OR

(95% CI)

p

Control

n (%)

NSCLC

n (%)

OR

(95% CI)

p

VEGF

−634C > G

n = 295

n = 181

n = 88

n = 52

GG

150 (50.9)

94 (51.9)

1.00

48 (54.5)

24 (46.1)

1.00

0.61

GC

133 (45.1)

70 (38.7)

0.84

(0.57 - 1.24)

0.05

35 (39.8)

25 (48.1)

1.43

(0.70 - 2.90)

CC

12 (4.1)

17 (9.4)

2.26

(1.03 - 4.94)

5 (5.7)

3 (5.8)

1.20

(0.26 - 5.45)

GC+CC

145 (49.1)

87 (48.1)

0.96

(0.66 - 1.39)

0.82

40 (45.5)

28 (53.9)

1.40

(0.70 - 2.79)

0.34

VEGF

−2578C > A

n = 295

n = 181

n = 88

n = 52

CC

65 (22.0)

55 (30.4)

1.00

0.13

23 (26.1)

12 (23.1)

1.00

0.89

CA

159 (53.9)

87 (48.1)

0.65

(0.41 - 1.01)

44 (50.0)

28 (53.9)

1.22

(0.52 - 2.84)

AA

71 (24.1)

39 (21.6)

0.65

(0.38 - 1.10)

21 (23.9)

12 (23.1)

1.10

(0.40 - 2.96)

CA+ AA

230 (78.0)

126 (69.6)

0.65

(0.43 - 0.99)

0.04

65 (73.9)

40 (76.9)

1.18

(0.53 - 2.63)

0.69

VEGF +936C > T

n = 295

n = 181

n = 88

n = 52

CC

217 (73.6)

125 (69.1)

1.00

0.45

59 (67.0)

33 (63.5)

1.00

0.90

CT

70 (23.7)

48 (26.5)

1.19

(0.78 - 1.83)

24 (27.3)

16 (30.8)

1.19

(0.56 - 2.56)

TT

8 (2.7)

8 (4.4)

1.74

(0.64 - 4.74)

5 (5.7)

3 (5.8)

1.07

(0.24 - 4.78)

CT + TT

78 (26.4)

56 (30.9)

1.25

(0.83 - 1.87)

0.29

29 (33.0)

19 (36.5)

1.17

(0.57 - 2.40)

0.67